Loading
GT Biopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Breen Michael Martin, was filed 11 Apr 2023.
GT Biopharma, Inc.: what insiders have been doing
GT Biopharma, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of GT Biopharma, Inc. in twelve months, the latest record being from 15 August 2023.
Our records for GT Biopharma, Inc. go back to 2016, with 5 purchases and 20 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -28.4 m USD.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
44
Thresholds
n/a
Buy Volume
€67,561
5 ops. · all time
Sell Volume
€188,791
20 ops. · all time
Since the insiders bought
- -72.8%Entry US$14.70 · Close at T+365 US$4.00
- -74.4%Entry US$15.60 · Close at T+365 US$4.00
- -69.5%Entry US$177.30 · Close at T+365 US$54.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.85
Analyst consensus
1 analystsUS$75.00Target US$75.00(+995%)US$75.00
Income statement
EBITDA-US$28.2M
Net income-US$28.4M0.0% margin
Valuation
P/Book3.4x
Beta0.86
Balance sheet & cash
Market capUS$14.1M
Free Cash Flow-US$12.9M
Profitability & ownership
ROE-113.5%
ROA-158.2%
% insiders10.3%
% institutions8.4%
Last declaration on 15 August 2023
Declarations44 total
200,000 shares@ US$0.28769.5% of flowCommon StockSEC:0001493152-23-029061:0
200,000 shares@ US$0.28769.5% of flowCommon StockSEC:0001493152-23-029059:0
50,000 shares@ US$0.5030.5% of flowCommon StockSEC:0001493152-23-011888:0
Canonical exit: 10 Jul 2023 (T+90)
50,000 shares@ US$0.5030.5% of flowCommon StockSEC:0001493152-23-011772:0
Canonical exit: 5 Jul 2023 (T+90)
100,000 shares0Common StockSEC:0001493152-22-019872:1
100,000 shares0Common StockSEC:0001493152-22-019872:2
100,000 shares0Common StockSEC:0001493152-22-019872:0
278,058 shares0Common StockSEC:0001493152-22-019876:0
278,058 shares0Common StockSEC:0001654954-22-001643:0
40,243 shares@ US$3.4052.3% of flowCommon StockSEC:0001654954-21-012057:1
9,859 shares@ US$3.4012.8% of flowCommon StockSEC:0001654954-21-012057:2
278,058 shares0Common StockSEC:0001654954-21-012057:0
1,374 shares@ US$8.8745.8% of flowCommon StockSEC:0001654954-21-010887:1
Canonical exit: 22 Mar 2021 (T+90)
441 shares@ US$8.7314.5% of flowCommon StockSEC:0001654954-21-010887:2
Canonical exit: 22 Mar 2021 (T+90)
347,572 shares0Common StockSEC:0001654954-21-010887:3
3,268 shares@ US$3.14100.0% of flowCommon StockSEC:0001654954-21-010887:0
Canonical exit: 14 Feb 2021 (T+90)
50,000 shares@ US$0.306.7% of flowCommon StockSEC:0001356710-20-000003:0
50,000 shares@ US$0.337.3% of flowCommon StockSEC:0001356710-20-000003:1
35,722 shares@ US$0.345.4% of flowCommon StockSEC:0001356710-20-000003:2
47,978 shares@ US$0.408.5% of flowCommon StockSEC:0001356710-20-000003:3
50,000 shares@ US$0.306.7% of flowCommon StockSEC:0001356710-20-000002:0
50,000 shares@ US$0.306.7% of flowCommon StockSEC:0001356710-20-000002:1
50,000 shares@ US$0.316.9% of flowCommon StockSEC:0001356710-20-000002:2
50,000 shares@ US$0.306.6% of flowCommon StockSEC:0001356710-20-000002:3
50,000 shares@ US$0.255.6% of flowCommon StockSEC:0001356710-20-000001:0
25 of 44 declarations
About GT Biopharma, Inc.
GT Biopharma, Inc. (NASDAQ: GTBP) is a United States-based clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. The company is focused on immuno-oncology and is developing therapies built around its proprietary TriKE® platform, a natural killer (NK) cell engager approach designed to help the immune system identify and attack cancer cells. For investors, GT Biopharma should be viewed as a development-stage biotech story in which the main drivers are clinical execution, platform differentiation, and access to capital rather than current commercial revenue. ([gtbiopharma.com](https://www.gtbiopharma.com/?utm_source=openai))
GT Biopharma has gone through several corporate iterations over time before evolving into its current oncology-focused profile. SEC filings describe the company as a Delaware corporation with earlier legacy names, while its strategic repositioning was materially advanced by the 2017 merger with Georgetown Translational Pharmaceuticals. Its headquarters are in San Francisco, California, placing it in one of the most important biotechnology hubs in the United States. ([gtbiopharma.com](https://www.gtbiopharma.com/news-media/press-releases/detail/124/gt-biopharma-inc-announces-closing-of-oxis-international?utm_source=openai))
Read moreShow less
Operationally, the company’s core business is the development of TriKE®-based drug candidates across oncology indications. Two programs have recently attracted the most attention: GTB-3650, which is being developed for CD33-expressing hematologic malignancies, and GTB-5550, a B7-H3-targeted NK cell engager for solid tumors. GT Biopharma describes the platform as combining tumor targeting with NK-cell activation through CD16, while also incorporating an IL-15 component intended to stimulate NK-cell proliferation and activation. ([gtbiopharma.com](https://www.gtbiopharma.com/product-pipeline/overview?utm_source=openai))
In competitive terms, GT Biopharma remains a small, highly specialized oncology biotech competing in a crowded field that includes much larger immunotherapy and oncology developers. Its investment case rests on whether the TriKE® platform can generate clinically meaningful differentiation and eventually translate into value-creating data readouts. Like most micro-cap clinical biotechs, it is still dependent on external financing and has not yet built a recurring commercial business. ([ir.gtbiopharma.com](https://ir.gtbiopharma.com/press-releases/detail/306/gt-biopharma-reports-full-year-2025-financial-results?utm_source=openai))
Recent developments are especially relevant. In January 2026, the company announced submission of the GTB-5550 IND, and in early February 2026 it disclosed FDA clearance of that IND, with a phase 1 basket trial expected to begin in mid-2026. In March 2026, GT Biopharma reported full-year 2025 results and said it had about $9 million of pro forma cash as of January 31, 2026, which it expects to fund operations through the fourth quarter of 2026. These updates underscore a pre-commercial biotech with meaningful clinical milestones ahead, but also with continuing financing and execution risk. ([ir.gtbiopharma.com](https://ir.gtbiopharma.com/press-releases/detail/306/gt-biopharma-reports-full-year-2025-financial-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
